Resminostat is under clinical development by 4SC and currently in Phase II for Mycosis Fungoides. According to GlobalData, Phase II drugs for Mycosis Fungoides have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Resminostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Resminostat overview
Resminostat (4SC-201, YHI-1001, BYK408740) is under development for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides, sezary syndrome, mycosis fungoides and sezary syndrome. It is administered by oral route in the form of film coated tablet. It acts by targeting histone deacetylase I, IIb and IV. The drug candidate is developed based on Virtual High Throughput Screening (vHTS) platform known as 4SCan. It was also under development for the treatment of advanced colorectal cancer, non-small cell lung cancer, replased or refractory Hodgkin's lymphoma, gall bladder cancer, pancreatic cancer, advanced hepatocellular carcinoma, bile duct cancer (cholangiocarcinoma) and other solid tumors.
4SC overview
4SC is a biotechnology company. It is primarily engaged in the development of small-molecule drugs for the treatment of cancer, specifically in areas with a high unmet medical need. The company’s main focus is on the development and commercialization of its primary drug candidate, resminostat (Kinselby), an orally administered histone deacetylase (HDAC) inhibitor. Resminostat is being developed as a maintenance therapy for advanced-stage cutaneous T-cell lymphoma (CTCL). The drug has shown potential in inhibiting tumor progression and metastasis, inducing tumor regression, and enhancing the body’s immune response to cancer. 4SC is headquartered in Planegg-Martinsried, Germany.
For a complete picture of Resminostat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
